All about the Catalent company from Anagni at the center of the Astrazeneca case
Shareholders, income statement and board of directors of Catalent, the company based in Anagni where the Astrazeneca vaccine is filled
The European Commission was not paying attention. And so he asked Italy to go check it out. Result: it was discovered that 29 million doses of the AstraZeneca vaccine are stored at Catalent in Anagni, in the province of Frosinone, which is filled in the Lazio plant.
The Anglo-Swedish pharmaceutical company AstraZeneca is once again the protagonist, after the discovery that 29 million doses of vaccine are stored in the Catalent plant in Anagni. The Nas have launched an inspection and Draghi has assured that there will be maximum vigilance.
The reaction of Brussels had been very harsh which, with the emergency commissioner Covid Breton, had threatened the blocking of exports, ensuring that those vials stored in Anagni would not leave the European Union, except for a small part destined for poor countries . The reaction of the British Prime Minister Johnson had, in turn, threatened retaliation in the event that "arbitrary blocks" were practiced.
ASTRAZENECA'S CLARIFICATIONS
The company yesterday specified that they were produced outside the EU borders, adding that they are partly destined for European countries and partly for those that are part of the Covax program, ie low-income countries: "There are currently no planned exports if not to countries of the WHO Covax international program. There are 13 million vaccine doses pending quality control release at Covax as part of our commitment to supply millions of doses to low-income countries. The vaccine – the company explains – was produced outside the EU and brought to the Anagni plant to be filled in vials ». While "another 16 million doses are awaiting quality control before being shipped to Europe".
THE PUFFS OF BRUSSELS AGAINST ASTRAZENECA
But the information released by the European Commission diverges on the origin of the vaccines, Corriere della Sera stressed . For the EU Commissioner, Thierry Breton, head of the task force for the production of vaccines, "these are doses produced mainly in the AstraZeneca plant, Halix, located in the Netherlands which has not yet obtained authorization from the European Agency for medicines. When they get the visa as a production workshop, they can be distributed among the Twenty-seven, ”he added.
THE WORDS OF DRAGONS ABOUT CATALENT
In short, the story also has the characteristics of yellow. Which is not even clarified by the clarification of Mario Draghi himself: "Saturday evening I received a phone call from the president of the Commission von der Leyen" who indicated the presence of batches of AstraZeneca vaccine that did not appear in the Commission's accounts and that would have been "filled in. Anagni, «I was advised to order an inspection. That same evening I asked Minister Speranza to send the Nas: they went immediately and in the morning they identified those excess lots. The lots have been blocked and today two have left for Belgium, directed to the parent company. Where they will go I do not know, meanwhile the surveillance continues for the remaining lots in the Anagni plant ». All outgoing batches are controlled by the Nas. And there is also what Brussels defines as the risk of opaque triangulations of vaccine destinations.
WHAT CATALENT SAYS
The 800 employees of Catalent , the American multinational that deals with the filling of AstraZeneca in Anagni, find themselves today at the center of the international dispute over vaccines. The Nas “arrived on Saturday evening. They spent the night here. They left on Tuesday evening ”, Barbara Sambuco, the plant manager, explained today in an interview with La Repubblica . “They found no irregularities. The vaccine is stopped in the refrigerators waiting for the chemical and sterility checks to be completed, which "can last up to 18 days". We must “be sure that the vials do not contain microorganisms. We take a few as a sample and let them incubate for at least 15 days. If no microbes have formed at that point, we are sure that they are sterile ”, and there are also AstraZeneca's controls on the raw material” which take two or three months. When the results arrive, “AstraZeneca gives us the green light and the vaccines can leave Anagni” and go “to two distribution centers in Belgium. From there they leave for their final destination ”. Even if the vaccines are destined outside the EU, it is Catalent who asks for permission to export, “it is the European standards. We are the manufacturing plant. It is up to us to send a pec to the Farnesina and ask for the green light to export. but only at the request of Astrazeneca ”. For these doses it was not done, “we do it if Astra Zeneca asks us. We are only executors ”.
But who is Catalent, what does it do and whose is it? Here is the identity card of the Italian company controlled by the American group of the same name.
WHAT CATALENT DOES
Catalent Anagni Srl is active in the production and packaging of medicines, active ingredients, serums, vaccines and medical surgical aids.
PROPERTY AND MANAGEMENT
The company, subject to management and coordination by Catalent Italy Holding Srl, is controlled by the multinational Catalent Pharma Solution, active in the development and production of drugs, biological products and gene therapies, based in Somerset, New Jersey.
THE ROLE OF BRISTOL-MYERS
Catalent Anagni was previously owned by the biopharmaceutical company Bristol-Myers Squibb Company, which sold the manufacturing facility to the American multinational in July 2020.
THE MANAGEMENT
Chairman of the Board of Directors of Catalent Anagni is chaired by Mario Gargiulo. Other members of the board of directors are Quirino La Starza, Arnold Jonathan Armitage, Hermina Elisabeth Boerman Manjia.
THE NUMBERS
Catalent boasts as of 30 June 2020 (when it was still controlled by Bristol) a production value of 60,624,582 euros, with a profit of 8,579,815 euros. The management costs, as at 30 June 2020, amounted to 21,199,149 euros.
The company's equity is equal to 53,788,228 euros, with a share capital of 1,010,000 euros (with a loan from the shareholder Catalent Italy equal to 9,827,455 euros). The total value of the fixed assets is 37,901,842 euros. Payables amounted to € 49,891,015.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/tutto-sullazienda-catalent-di-anagni-al-centro-del-caso-astrazeneca/ on Thu, 25 Feb 2021 14:00:05 +0000.